Carcinoma, Renal Cell  >>  Torisel (temsirolimus)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

13 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Torisel (temsirolimus) / Pfizer
NCT00574483: Treatment of Advanced Renal Cell Carcinoma With Quinacrine

Withdrawn
2
0
US
quinacrine, CBLC102
Cleveland BioLabs
Renal Cell Carcinoma
01/08
01/08
NCT00494091: Study Evaluating The Safety, Efficacy & Pharmacokinetics Of Temsirolimus(CCI-779) In Subjects With Advanced Renal Cell Carcinoma

Checkmark P2 data
Jul 2012 - Jul 2012: P2 data
Completed
2
82
Japan, RoW
Temsirolimus (CCI-779), Torisel
Pfizer
Advanced Renal Cell Carcinoma
05/11
03/12
TORAVA, NCT00619268 / 2007-003369-42: Combination of Temsirolimus and Bevacizumab in Patient With Metastatic Renal Cell Carcinoma

Checkmark P2 data-ASCO
Jun 2012 - Jun 2012: P2 data-ASCO
Checkmark P2 data
Jun 2011 - Jun 2011: P2 data
Checkmark P2 data
More
Completed
2
160
Europe
Temsirolimus, Torisel®, Bevacizumab, Avastin®, Sunitinib, Sutent®, Interferon alpha-2a, Roféron®
Centre Leon Berard
Metastatic Renal Cell Carcinoma
02/12
02/12
NCT00979966 / 2009-010143-13: Study in Non-Clear Cell Renal Carcinoma (Ncc-RCC) Temsirolimus Versus Sunitinib

Completed
2
22
Europe
Temsirolimus, Sunitinib
Central European Society for Anticancer Drug Research
Non-clear Cell Renal Cell Cancer
07/12
 
NCT00378703: Bevacizumab, Sorafenib Tosylate, and Temsirolimus in Treating Patients With Metastatic Kidney Cancer

Checkmark ASCO-GU 2013
Feb 2013 - Feb 2013: ASCO-GU 2013
Completed
2
361
US, RoW
Bevacizumab, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF rhuMAb, Avastin, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar FKB238, Bevacizumab Biosimilar MIL60, Bevacizumab Biosimilar QL 1101, BEVACIZUMAB, LICENSE HOLDER UNSPECIFIED, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, Laboratory Biomarker Analysis, Pharmacological Study, Sorafenib Tosylate, BAY 43-9006 Tosylate, BAY 54-9085, Nexavar, sorafenib, Temsirolimus, CCI-779, CCI-779 Rapamycin Analog, Cell Cycle Inhibitor 779, Rapamycin Analog, Rapamycin Analog CCI-779, Torisel
National Cancer Institute (NCI)
Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v7
02/14
03/17
SERCC, NCT01342627 / 2010-019726-14: Sorafenib in Elderly Patients With Metastatic Renal Cell Carcinoma

Terminated
2
4
Europe
Sorafenib, Nexavar
Centro di Riferimento Oncologico - Aviano
Metastatic Renal Cell Carcinoma
09/14
09/15
NCT00782275: Avastin and Temsirolimus Following Tyrosine Kinase Inhibitor Failure in Patients With Advanced Renal Cell Carcinoma

Checkmark ASCO 2014
May 2014 - May 2014: ASCO 2014
Completed
2
41
US
bevacizumab, avastin, temsirolimus, torisel
Beth Israel Deaconess Medical Center, Genentech, Inc., Dana-Farber Cancer Institute, Brigham and Women's Hospital, Vanderbilt University Medical Center
Renal Cell Carcinoma, Kidney Cancer
05/15
05/15
NCT00923845: Low-Intensity Stem Cell Transplantation With Multiple Lymphocyte Infusions to Treat Advanced Kidney Cancer

Completed
2
25
US
Pentostatin, Nipent, Sirolimus, Rapamune, Cyclophosphamide, Cytoxan, Allogeneic Hematopoietic Stem Cell Transplant (HSCT), Th2 rapa cells, Donor Lymphocyte Harvest, Induction Therapy, GVHD prophylaxis, Donor Hematopoietic Stem Cell Harvest
National Cancer Institute (NCI)
Renal Cell Carcinoma, Graft-Versus-Host Disease, Engraftment Syndrome
06/15
06/17
NCT01264341 / 2010-020664-38: Efficacy and Safety of Bevacizumab/Temsirolimus Combination to Treat Advanced Renal Cell Carcinoma

Terminated
2
39
Europe
Bevacizumab, Temsirolimus
Hellenic Cooperative Oncology Group
Kidney Cancer
07/15
07/15
NCT02479490 / 2015-002419-14: PRednisone Plus EVerolimus in Patients With Metastatic Renal Cell Cancer After Failure of VEGFR -TKI

Terminated
2
8
Europe
Prednisone + Everolimus, prednisone, everolimus
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
Metastatic Renal Cancer
05/17
09/17
NCT02560012: Personalized Targeted Inhibitors Treatment in Renal Cell Cancer

Terminated
2
4
US
Sunitinib, Sutent, Temsirolimus, Torisel, Sorafenib, Nexavar, Pazopanib, Votrient, Everolimus, Afinitor, Axitinib, Inlyta
The University of Texas Health Science Center, Houston
Carcinoma, Renal Cell
07/17
07/17
NCT02122003: Second Line Sorafenib After Pazopanib in Patients With RCC

Terminated
2
16
Europe
Sorafenib, Nexavar
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Metastatic Renal Cell Carcinoma
11/17
11/17
NCT02423954: Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus)

Checkmark WCGC 2016 - metastatic colon cancer and pancreatic adenocarcinoma
Jun 2016 - Jun 2016: WCGC 2016 - metastatic colon cancer and pancreatic adenocarcinoma
Terminated
1/2
33
US
Temsirolimus, Torisel, Irinotecan, Camptosar, Irinotecan + capecitabine, Camptosar + Xeloda, nivolumab, Opdivo
Western Regional Medical Center
Advanced Cancer, Pancreatic Cancer, Renal Cell Cancer, Non Small Cell Lung Cancer, Colorectal Carcinoma, Endometrial, Uterine
11/17
11/17

Download Options